CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+10.92%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$657M
AUM Growth
+$657M
(-1%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
2.91%
Top 10 Holdings %
Top 10 Hldgs %
66.42%
Holding
38
New
3
Increased
15
Reduced
6
Closed
6
Top Buys
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$42.8M |
| 2 |
Vera Therapeutics
VERA
|
$21.9M |
| 3 |
Akero Therapeutics
AKRO
|
$9.68M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$9.19M |
| 5 |
Cabaletta Bio
CABA
|
$6.82M |
Top Sells
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$32.4M |
| 2 |
Arcellx
ACLX
|
$18.3M |
| 3 |
Enliven Therapeutics
ELVN
|
$16.7M |
| 4 |
4D Molecular Therapeutics
FDMT
|
$13.3M |
| 5 |
Aclaris Therapeutics
ACRS
|
$10.1M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$2.98B
| $66M | 10.05% | 1,845,000 +185,889 | +11% | +$6.65M |
|
2
Viridian Therapeutics
VRDN
$1.5B
| $55.7M | 8.48% | 2,189,659 +169,493 | +8% | +$4.31M |
|
3
Merus
MRUS
$4.98B
| $54.3M | 8.26% | 2,950,000 +217,433 | +8% | +$4M |
|
4
Cogent Biosciences
COGT
$1.69B
| $51.5M | 7.84% | 4,772,421 +452,481 | +10% | +$4.88M |
|
|
BLU
5
DELISTED
BELLUS Health Inc.
BLU
| $47.4M | 7.21% | 6,579,359 +1,275,802 | +24% | +$9.19M |
|
|
AMAM
6
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $42.8M | 6.52% | +4,803,447 | New | +$42.8M |
|
|
7
Enliven Therapeutics
ELVN
$1.2B
| $37.9M | 5.77% | 1,731,365 -763,429 | -31% | -$16.7M |
|
|
8
Akero Therapeutics
AKRO
$3.74B
| $30.2M | 4.6% | 790,000 +252,924 | +47% | +$9.68M |
|
9
Nuvalent
NUVL
$5.52B
| $28M | 4.27% | 1,075,000 +161,379 | +18% | +$4.21M |
|
10
Immunovant
IMVT
$2.56B
| $22.3M | 3.4% | 1,440,999 +290,494 | +25% | +$4.51M |
|
|
11
Vera Therapeutics
VERA
$1.38B
| $21.9M | 3.34% | +2,824,029 | New | +$21.9M |
|
12
Syndax Pharmaceuticals
SNDX
$1.41B
| $18M | 2.75% | 853,884 +165,439 | +24% | +$3.49M |
|
13
Celldex Therapeutics
CLDX
$1.47B
| $17.8M | 2.72% | 495,823 | – | – |
|
|
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
| $17.7M | 2.69% | 2,025,000 -3,713,500 | -65% | -$32.4M |
|
|
15
Cabaletta Bio
CABA
$133M
| $15.2M | 2.31% | 1,835,000 +824,641 | +82% | +$6.82M |
|
16
Kura Oncology
KURA
$686M
| $14.7M | 2.24% | 1,204,958 +105,551 | +10% | +$1.29M |
|
17
Arrowhead Research
ARWR
$3.05B
| $14.6M | 2.22% | 575,000 +112,889 | +24% | +$2.87M |
|
18
Celcuity
CELC
$2.17B
| $14.3M | 2.17% | 1,390,772 +62,820 | +5% | +$644K |
|
|
RXDX
19
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $13.6M | 2.08% | 127,156 | – | – |
|
|
ALPN
20
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $10.2M | 1.56% | 1,325,000 | – | – |
|
21
Day One Biopharmaceuticals
DAWN
$769M
| $9.89M | 1.51% | 739,661 | – | – |
|
22
Avidity Biosciences
RNA
$5.99B
| $9.07M | 1.38% | 590,705 | – | – |
|
23
Enanta Pharmaceuticals
ENTA
$180M
| $8.79M | 1.34% | 217,253 -6,241 | -3% | -$252K |
|
|
ALLK
24
DELISTED
Allakos
ALLK
| $8.46M | 1.29% | 1,900,000 +256,500 | +16% | +$1.14M |
|
25
Vaxcyte
PCVX
$4B
| $7.5M | 1.14% | 200,000 +26,519 | +15% | +$994K |
|